AXSM — Axsome Therapeutics
Median target
$273.5
calls from the last 12 months
Implied return
+27.6%
median target vs. price
Coverage
19 analysts · 23 calls
updated in the last 12 months
Consensus
18/1/0+18 net
Buy / Hold / Sell
Which analysts are behind AXSM's consensus?
See every current rating, price target and the analysts' track records for Axsome Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 19 analysts with calls on AXSM updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
AXSM elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-09-03 | Insiders | Jacobson Mark L.Chief Operating Officer | Insider sale | 10.0K sh @ $208.65 · planned trade | $2.1M |
| 2026-08-06 | Insiders | Tabuteau HerriotChief Executive Officer | Insider sale | 4.7K sh @ $213.95 · planned trade | $997K |
| 2026-08-05 | Insiders | Tabuteau HerriotChief Executive Officer | Insider sale | 45.0K sh @ $212.01 · planned trade | $9.5M |
| 2022-06-16 | Congress | Christopher L. JacobsNY-NY27 | Purchase | since trade +855.7%, vs market +736.2% | $15K–$50K |
More: congressional trades on AXSM · insider activity · executive branch · trending